Article(id=1329835356075176571, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329835237376373459, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2024.01.012, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1684425600000, receivedDateStr=2023-05-19, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794987056033, onlineDateStr=2026-11-18, pubDate=1704816000000, pubDateStr=2024-01-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794987056033, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794987056033, creator=13701087609, updateTime=1794987056033, updator=13701087609, issue=Issue{id=1329835237376373459, tenantId=1146029695717560320, journalId=1319690329412173987, year='2024', volume='45', issue='1', pageStart='1', pageEnd='102', issueExtLink='null', onlineDate='null', pubDate='1704816000000', pubDateStr='2024-01-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794987027734, creator='13701087609', updateTime=1794988176831, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329840057474724591, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329835237376373459, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329840057478918896, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329835237376373459, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=71, endPage=76, ext={EN=ArticleExt(id=1329835356276503164, articleId=1329835356075176571, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Research progress of antibody drugs targeting interleukin-4 receptor, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Interleukin (IL)-4 is a multipotent cytokine that specifically binds to IL-4 receptor (IL-4R) on the cell surface to exert its biological effects. The expression level of IL-4R on the cell surface is relatively low under normal conditions and increases after being stimulated by hormones, stress and inflammation. At present, it has been found that IL-4/IL-4R plays an important role in the occurrence and development of atopic dermatitis, asthma, malignant tumor and other diseases. Currently, monoclonal antibody drugs targeting IL-4Rα have been used for clinical treatment, particularly for type 2 inflammation, and more than 8 therapeutic agents are in clinical research phase. This article reviewed the IL-4/IL-4R signaling pathway and related diseases, and the current status of research on therapeutic monoclonal antibody drugs targeting IL-4R and their clinical applications.

, authors=Ao ZHANG, Liping XIE*, authorsList=Ao ZHANG, Liping XIE, authorCompany=null, correspAuthors=Liping XIE, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329835356498801277, articleId=1329835356075176571, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=靶向白介素-4受体的抗体类药物研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

白介素(interleukin,IL)-4是一种多效细胞因子,特异性地与细胞表面的IL-4受体(IL-4 receptor,IL-4R)结合后发挥其生物学效应。正常情况下细胞表面IL-4R表达水平较低,当受到激素、应激及炎症等刺激后表达量增高。目前发现IL-4/IL-4R在特应性皮炎(atopic dermatitis)、哮喘(asthma)及恶性肿瘤等疾病的发生、发展中起重要作用。当前,已有针对IL-4Rα靶点的抗体药物用于临床治疗,对于2型炎症疗效尤为突出,超过8个治疗型药物处在临床研究阶段。该文主要对IL-4/IL-4R信号通路及其相关疾病、靶向IL-4R的治疗性抗体药物研究现状及其临床应用作综述。

, authors=张澳, 谢丽萍*, authorsList=张澳, 谢丽萍, authorCompany=null, correspAuthors=谢丽萍, authorNote=

张澳,硕士研究生,研究方向:生物大分子药物研发。

, correspAuthorsNote=
谢丽萍,研究员,研究方向:生物大分子药物研发。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=CIIdYmEF3m4lQCkQTXXH4A==, magXml=2FNH0881Dxb/pxO/4E6TCg==, pdfUrl=null, pdf=HauKk2Csr2mbgpSEN/pRgQ==, pdfFileSize=1556406, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=ixnyyojdV1HpMg8R87Czew==, mapNumber=null, fund=null)}, authors=[Author(id=1329835356784013954, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329835356855317124, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, authorId=1329835356784013954, language=EN, stringName=Ao ZHANG, firstName=Ao, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835356922425989, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, authorId=1329835356784013954, language=CN, stringName=张澳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海 201203, bio={"content":"

张澳,硕士研究生,研究方向:生物大分子药物研发。

"}, bioImg=null, bioContent=

张澳,硕士研究生,研究方向:生物大分子药物研发。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835356691739262, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, xref=null, ext=[AuthorCompanyExt(id=1329835356700127871, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, companyId=1329835356691739262, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1329835356708516480, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, companyId=1329835356691739262, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])]), Author(id=1329835356993729159, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329835357090198153, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, authorId=1329835356993729159, language=EN, stringName=Liping XIE, firstName=Liping, middleName=null, lastName=XIE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835357157307018, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, authorId=1329835356993729159, language=CN, stringName=谢丽萍, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835356691739262, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, xref=null, ext=[AuthorCompanyExt(id=1329835356700127871, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, companyId=1329835356691739262, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1329835356708516480, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, companyId=1329835356691739262, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])])], keywords=[Keyword(id=1329835357262164619, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, language=EN, orderNo=1, keyword=interleukin-4 receptor), Keyword(id=1329835357341856396, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, language=EN, orderNo=2, keyword=targeted therapy), Keyword(id=1329835357421548173, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, language=EN, orderNo=3, keyword=antibody drug), Keyword(id=1329835357513822862, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, language=CN, orderNo=1, keyword=白介素-4受体), Keyword(id=1329835357597708943, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, language=CN, orderNo=2, keyword=靶向治疗), Keyword(id=1329835357664817808, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, language=CN, orderNo=3, keyword=抗体药物)], refs=[Reference(id=1329835357786452625, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Stark JM, Tibbitt CA, Coquet JM. The metabolic requirements of Th2 cell differentiation[J]. Front Immunol, 2019, 10: 2318., articleTitle=null, refAbstract=null), Reference(id=1329835357891310226, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Junttila IS. Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes[J]. Front Immunol, 2018, 9: 888., articleTitle=null, refAbstract=null), Reference(id=1329835357996167827, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Kerneur C, Cano CE, Olive D. Major pathways involved in macrophage polarization in cancer[J]. Front Immunol, 2022, 13: 1026954., articleTitle=null, refAbstract=null), Reference(id=1329835358080053908, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Daines JM, Schellhardt L, Wood MD. The role of the IL-4 signaling pathway in traumatic nerve injuries[J]. Neurorehabil Neural Repair, 2021, 35(5): 431-443., articleTitle=null, refAbstract=null), Reference(id=1329835358197494421, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Zipp F, Bittner S, Schafer DP. Cytokines as emerging regulators of central nervous system synapses[J]. Immunity, 2023, 56(5): 914-925., articleTitle=null, refAbstract=null), Reference(id=1329835358335906454, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Gandhi H, Worch R, Kurgonaite K, et al. Dynamics and interaction of interleukin-4 receptor subunits in living cells[J]. Biophys J, 2014, 107(11): 2515-2527., articleTitle=null, refAbstract=null), Reference(id=1329835358461735575, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Bernstein ZJ, Shenoy A, Chen A, et al. Engineering the IL-4/IL-13 axis for targeted immune modulation[J]. Immunol Rev, 2023, 320(1): 29-57., articleTitle=null, refAbstract=null), Reference(id=1329835358562398872, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Keegan AD, Zamorano J, Keselman A, et al. IL-4 and IL-13 receptor signaling from 4PS to insulin receptor substrate 2: there and back again, a historical view[J]. Front Immunol, 2018, 9: 1037., articleTitle=null, refAbstract=null), Reference(id=1329835358646284953, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Furue M. Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis[J]. Int J Mol Sci, 2020, 21(15): 5382., articleTitle=null, refAbstract=null), Reference(id=1329835358713393818, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=陈嘉雯, 姚志荣. 特应性皮炎的生物学分型及靶向治疗进展[J]. 中国麻风皮肤病杂志, 2019, 35(3): 184-188., articleTitle=null, refAbstract=null), Reference(id=1329835358818251419, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Bjerre RD, Holm JB, Palleja A, et al. Skin dysbiosis in the microbiome in atopic dermatitis is site-specific and involves bacteria, fungus and virus[J]. Bio Med Central Microbiol, 2021, 21(1): 256., articleTitle=null, refAbstract=null), Reference(id=1329835358902137500, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis[J]. J Allergy Clin Immunol, 2019, 143(1): 155-172., articleTitle=null, refAbstract=null), Reference(id=1329835358986023581, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Callewaert C, Nakatsuji T, Knight R, et al. IL-4Rα blockade by dupilumab decreases staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis[J]. J Invest Dermatol, 2020, 140(1): 191-202., articleTitle=null, refAbstract=null), Reference(id=1329835359053132446, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10086): 2287-2303., articleTitle=null, refAbstract=null), Reference(id=1329835359116047007, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis[J]. N Engl J Med, 2016, 375(24): 2335-2348., articleTitle=null, refAbstract=null), Reference(id=1329835359183155872, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=顾建青, 高翔, 孙劲旅, 等. 度普利尤单抗治疗中重度特应性皮炎初步临床观察[J]. 中华临床免疫和变态反应杂志, 2021, 15(4): 370-375., articleTitle=null, refAbstract=null), Reference(id=1329835359262847649, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Pelaia C, Pelaia G, Crimi C, et al. Biological therapy of severe asthma with dupilumab, a dual receptor antagonist of interleukins 4 and 13[J]. Vaccines (Basel), 2022, 10(6): 974., articleTitle=null, refAbstract=null), Reference(id=1329835359376093858, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Guruprasath P, Kim J, Gunassekaran GR, et al. Interleukin-4 receptor-targeted delivery of Bcl-xL siRNA sensitizes tumors to chemotherapy and inhibits tumor growth[J]. Biomaterials, 2017, 142: 101-111., articleTitle=null, refAbstract=null), Reference(id=1329835359443202723, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Kang MA, Lee J, Ha SH, et al. Interleukin-4Rα (IL-4Rα) and IL-13Rα1 are associated with the progress of renal cell carcinoma through Janus kinase 2 (JAK2)/forkhead box O3 (FOXO3) pathways[J]. Cancers (Basel), 2019, 11(9): 1394., articleTitle=null, refAbstract=null), Reference(id=1329835359510311588, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Shi J, Song X, Traub B, et al. Involvement of IL-4, IL-13 and their receptors in pancreatic cancer[J]. Int J Mol Sci, 2021, 22(6): 2998., articleTitle=null, refAbstract=null), Reference(id=1329835359577420453, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Joshi BH, Leland P, Lababidi S, et al. Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease[J]. Cancer Med, 2014, 3(6): 1615-1628., articleTitle=null, refAbstract=null), Reference(id=1329835359661306534, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Melo-Cardenas J, Bezavada L, Crawford JC, et al. IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms[J]. Blood, 2022, 140(26): 2805-2817., articleTitle=null, refAbstract=null), Reference(id=1329835359766164135, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Rahal OM, Wolfe AR, Mandal PK, et al. Blocking interleukin (IL)4- and IL13-mediated phosphorylation of STAT6 (Tyr641) decreases M2 polarization of macrophages and protects against macrophage-mediated radioresistance of inflammatory breast cancer[J]. Int J Radiat Oncol Biol Phys, 2018, 100(4): 1034-1043., articleTitle=null, refAbstract=null), Reference(id=1329835359850050216, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Gangadaran P, Gunassekaran GR, Rajendran RL, et al. Interleukin-4 receptor targeting peptide decorated extracellular vesicles as a platform for in vivo drug delivery to thyroid cancer[J]. Biomedicines, 2022, 10(8): 1978., articleTitle=null, refAbstract=null), Reference(id=1329835359917159081, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Sarangthem V, Yi A, Kim Y, et al. Therapeutic effect of IL-4 receptor-targeting pro-apoptotic peptide (AP1-ELP-KLAK) in glioblastoma tumor model[J]. Int J Nanomedicine, 2021, 16: 5039-5052., articleTitle=null, refAbstract=null), Reference(id=1329835359975879338, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=De Groot AE, Myers KV, Krueger TEG, et al. Targeting interleukin 4 receptor α on tumor-associated macrophages reduces the pro-tumor macrophage phenotype[J]. Neoplasia, 2022, 32: 100830., articleTitle=null, refAbstract=null), Reference(id=1329835360034599595, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Fieldes M, Bourguignon C, Assou S, et al. Targeted therapy in eosinophilic chronic obstructive pulmonary disease[J]. ERJ Open Res, 2021, 7(2): 00437-2020., articleTitle=null, refAbstract=null), Reference(id=1329835360097514156, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts[J]. N Engl J Med, 2023, 389(3): 205-214., articleTitle=null, refAbstract=null), Reference(id=1329835360160428717, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Deleuran M, Thaçi D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study[J]. J Am Acad Dermatol, 2020, 82(2): 377-388., articleTitle=null, refAbstract=null), Reference(id=1329835360244314798, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=康诺亚生物医药科技(成都)有限公司. 一种自免疫抑制剂及其应用: 中国, WO2019228405A1[P]. 2019-12-05., articleTitle=null, refAbstract=null), Reference(id=1329835360311423663, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhao Y, Zhang J, Yang B, et al. Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 2b trial[J]. Chin Med J (Engl), 2023, doi: 10.1097/CM9.0000000000002747., articleTitle=null, refAbstract=null), Reference(id=1329835360403698352, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang Y, Yan B, Shen S, et al. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial[J]. E Clin Med, 2023, 61: 102076., articleTitle=null, refAbstract=null), Reference(id=1329835360470807217, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang J, Li P, Guo J, et al. CBP-201, a next-generation IL-4Rα antibody, achieved all primary and sec-ondary efficacy endpoints in the treatment of adults with moderate-to-severe atopic dermatitis (AD): a randomized, double-blind, pivotal trial in China (CBP-201-CN002)[C]//Proceedings of the American Academy of Dermatology 2023 Annual Meeting, New Orleans: American Academy of Dermatology, 2023: 17-21., articleTitle=null, refAbstract=null), Reference(id=1329835360537916082, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Silverberg JI, Strober B, Feinstein B, et al. Efficacy and safety of rademikibart (CBP-201), a next-generation monoclonal antibody targeting IL-4Rα, in adults with moderate-to-severe atopic dermatitis: a phase 2 randomized trial (CBP-201-WW001)[J]. J Allergy Clin Immunol, 2023, doi: 10.1016/j.jaci.2023.11.924., articleTitle=null, refAbstract=null), Reference(id=1329835360613413555, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Matschiner G, Fitzgerald MF, Moebius U, et al. Elarekibep (PRS-060/AZD1402), a new class of inhaled Anticalin medicine targeting IL-4Ra for type 2 endotype asthma[J]. J Allergy Clin Immunol, 2023, 151(4): 966-975., articleTitle=null, refAbstract=null), Reference(id=1329835360697299636, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=BioSpace. Pieris pharmaceuticals announces successful completion of safety milestone and initiation of efficacy portion of phase 2a trial of PRS-060/AZD1402[EB/OL]. [2023-08-01]. https://www.biospace.com/article/releases/pieris-pharmaceuticals-announces-successful-completion-of-safety-milestone-and-initiation-of-efficacy-portion-of-phase-2a-trial-of-prs-060-azd1402/?keywords=PRS-060%2fAZD1402., articleTitle=null, refAbstract=null), Reference(id=1329835360768602805, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=新药情报库. 重组抗IL-4Rα人源化单克隆抗体(上海三生国健)[EB/OL]. [2023-08-01]. https://synapse.zhihuiya.com/drug/1dc16e5e570d42b7b8d5bfd78969392b., articleTitle=null, refAbstract=null), Reference(id=1329835360848294582, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=洛启生物. 抗IL-4R单域抗体雾化液[J].[EB/OL]. [2023-08-01]. http://www.novamab.com/product/1.html., articleTitle=null, refAbstract=null), Reference(id=1329835360923792055, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=南京融捷康生物科技有限公司. 一种稳定的抗体制剂: 中国, WO2023226617A1[P]. 2023-11-30, articleTitle=null, refAbstract=null), Reference(id=1329835360995095224, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Walsh JT, Hendrix S, Boato F, et al. MHCⅡ-independent CD4+ T cells protect injured CNS neurons via IL-4[J]. J Clin Invest, 2015, 125(2): 699-714., articleTitle=null, refAbstract=null), Reference(id=1329835361066398393, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Chylikova J, Dvorackova J, Tauber Z, et al. M1/M2 macrophage polarization in human obese adipose tissue[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2018, 162(2): 79-82., articleTitle=null, refAbstract=null), Reference(id=1329835361141895866, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Karo-Atar D, Bitton A, Benhar I, et al. Therapeutic targeting of the interleukin-4/interleukin-13 signaling pathway: in allergy and beyond[J]. BioDrugs, 2018, 32(3): 201-220., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329835356691739262, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, xref=null, ext=[AuthorCompanyExt(id=1329835356700127871, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, companyId=1329835356691739262, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1329835356708516480, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, companyId=1329835356691739262, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.01.012, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.01.012, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2024.01.012, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2024.01.012, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1704816000000, fullTextJson=null, articleText=null, reference=null)
收藏切换
靶向白介素-4受体的抗体类药物研究进展
张澳 , 谢丽萍 *
世界临床药物 | 综述评论 2024,45(1): 71-76
收起
收藏切换
世界临床药物 |综述评论 2024 , 45 (1) : 71 -76
靶向白介素-4受体的抗体类药物研究进展
全屏
[Author(id=1329835356784013954, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329835356855317124, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, authorId=1329835356784013954, language=EN, stringName=Ao ZHANG, firstName=Ao, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835356922425989, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, authorId=1329835356784013954, language=CN, stringName=张澳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海 201203, bio={"content":"

张澳,硕士研究生,研究方向:生物大分子药物研发。

"}, bioImg=null, bioContent=

张澳,硕士研究生,研究方向:生物大分子药物研发。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835356691739262, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, xref=null, ext=[AuthorCompanyExt(id=1329835356700127871, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, companyId=1329835356691739262, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1329835356708516480, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, companyId=1329835356691739262, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])]), Author(id=1329835356993729159, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329835357090198153, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, authorId=1329835356993729159, language=EN, stringName=Liping XIE, firstName=Liping, middleName=null, lastName=XIE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835357157307018, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, authorId=1329835356993729159, language=CN, stringName=谢丽萍, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835356691739262, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, xref=null, ext=[AuthorCompanyExt(id=1329835356700127871, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, companyId=1329835356691739262, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1329835356708516480, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835356075176571, companyId=1329835356691739262, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])])]
张澳, 谢丽萍*
作者信息
  • 中国医药工业研究总院,上海 201203
通讯作者:
谢丽萍,研究员,研究方向:生物大分子药物研发。
作者简介:

张澳,硕士研究生,研究方向:生物大分子药物研发。

Research progress of antibody drugs targeting interleukin-4 receptor
Ao ZHANG, Liping XIE*
Affiliations
  • China State Institute of Pharmaceutical Industry, Shanghai 201203, China
出版时间: 2024-01-10 doi: 10.13683/j.wph.2024.01.012
文章导航
收藏切换

白介素(interleukin,IL)-4是一种多效细胞因子,特异性地与细胞表面的IL-4受体(IL-4 receptor,IL-4R)结合后发挥其生物学效应。正常情况下细胞表面IL-4R表达水平较低,当受到激素、应激及炎症等刺激后表达量增高。目前发现IL-4/IL-4R在特应性皮炎(atopic dermatitis)、哮喘(asthma)及恶性肿瘤等疾病的发生、发展中起重要作用。当前,已有针对IL-4Rα靶点的抗体药物用于临床治疗,对于2型炎症疗效尤为突出,超过8个治疗型药物处在临床研究阶段。该文主要对IL-4/IL-4R信号通路及其相关疾病、靶向IL-4R的治疗性抗体药物研究现状及其临床应用作综述。

白介素-4受体  /  靶向治疗  /  抗体药物

Interleukin (IL)-4 is a multipotent cytokine that specifically binds to IL-4 receptor (IL-4R) on the cell surface to exert its biological effects. The expression level of IL-4R on the cell surface is relatively low under normal conditions and increases after being stimulated by hormones, stress and inflammation. At present, it has been found that IL-4/IL-4R plays an important role in the occurrence and development of atopic dermatitis, asthma, malignant tumor and other diseases. Currently, monoclonal antibody drugs targeting IL-4Rα have been used for clinical treatment, particularly for type 2 inflammation, and more than 8 therapeutic agents are in clinical research phase. This article reviewed the IL-4/IL-4R signaling pathway and related diseases, and the current status of research on therapeutic monoclonal antibody drugs targeting IL-4R and their clinical applications.

interleukin-4 receptor  /  targeted therapy  /  antibody drug
张澳, 谢丽萍. 靶向白介素-4受体的抗体类药物研究进展. 世界临床药物, 2024 , 45 (1) : 71 -76 . DOI: 10.13683/j.wph.2024.01.012
Ao ZHANG, Liping XIE. Research progress of antibody drugs targeting interleukin-4 receptor[J]. World Clinical Drug, 2024 , 45 (1) : 71 -76 . DOI: 10.13683/j.wph.2024.01.012

参考文献 引证文献
排序方式:
[1]
Stark JM, Tibbitt CA, Coquet JM. The metabolic requirements of Th2 cell differentiation[J]. Front Immunol, 2019, 10: 2318.
[2]
Junttila IS. Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes[J]. Front Immunol, 2018, 9: 888.
[3]
Kerneur C, Cano CE, Olive D. Major pathways involved in macrophage polarization in cancer[J]. Front Immunol, 2022, 13: 1026954.
[4]
Daines JM, Schellhardt L, Wood MD. The role of the IL-4 signaling pathway in traumatic nerve injuries[J]. Neurorehabil Neural Repair, 2021, 35(5): 431-443.
[5]
Zipp F, Bittner S, Schafer DP. Cytokines as emerging regulators of central nervous system synapses[J]. Immunity, 2023, 56(5): 914-925.
[6]
Gandhi H, Worch R, Kurgonaite K, et al. Dynamics and interaction of interleukin-4 receptor subunits in living cells[J]. Biophys J, 2014, 107(11): 2515-2527.
[7]
Bernstein ZJ, Shenoy A, Chen A, et al. Engineering the IL-4/IL-13 axis for targeted immune modulation[J]. Immunol Rev, 2023, 320(1): 29-57.
[8]
Keegan AD, Zamorano J, Keselman A, et al. IL-4 and IL-13 receptor signaling from 4PS to insulin receptor substrate 2: there and back again, a historical view[J]. Front Immunol, 2018, 9: 1037.
[9]
Furue M. Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis[J]. Int J Mol Sci, 2020, 21(15): 5382.
[10]
陈嘉雯, 姚志荣. 特应性皮炎的生物学分型及靶向治疗进展[J]. 中国麻风皮肤病杂志, 2019, 35(3): 184-188.
[11]
Bjerre RD, Holm JB, Palleja A, et al. Skin dysbiosis in the microbiome in atopic dermatitis is site-specific and involves bacteria, fungus and virus[J]. Bio Med Central Microbiol, 2021, 21(1): 256.
[12]
Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis[J]. J Allergy Clin Immunol, 2019, 143(1): 155-172.
[13]
Callewaert C, Nakatsuji T, Knight R, et al. IL-4Rα blockade by dupilumab decreases staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis[J]. J Invest Dermatol, 2020, 140(1): 191-202.
[14]
Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10086): 2287-2303.
[15]
Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis[J]. N Engl J Med, 2016, 375(24): 2335-2348.
[16]
顾建青, 高翔, 孙劲旅, 等. 度普利尤单抗治疗中重度特应性皮炎初步临床观察[J]. 中华临床免疫和变态反应杂志, 2021, 15(4): 370-375.
[17]
Pelaia C, Pelaia G, Crimi C, et al. Biological therapy of severe asthma with dupilumab, a dual receptor antagonist of interleukins 4 and 13[J]. Vaccines (Basel), 2022, 10(6): 974.
[18]
Guruprasath P, Kim J, Gunassekaran GR, et al. Interleukin-4 receptor-targeted delivery of Bcl-xL siRNA sensitizes tumors to chemotherapy and inhibits tumor growth[J]. Biomaterials, 2017, 142: 101-111.
[19]
Kang MA, Lee J, Ha SH, et al. Interleukin-4Rα (IL-4Rα) and IL-13Rα1 are associated with the progress of renal cell carcinoma through Janus kinase 2 (JAK2)/forkhead box O3 (FOXO3) pathways[J]. Cancers (Basel), 2019, 11(9): 1394.
[20]
Shi J, Song X, Traub B, et al. Involvement of IL-4, IL-13 and their receptors in pancreatic cancer[J]. Int J Mol Sci, 2021, 22(6): 2998.
[21]
Joshi BH, Leland P, Lababidi S, et al. Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease[J]. Cancer Med, 2014, 3(6): 1615-1628.
[22]
Melo-Cardenas J, Bezavada L, Crawford JC, et al. IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms[J]. Blood, 2022, 140(26): 2805-2817.
[23]
Rahal OM, Wolfe AR, Mandal PK, et al. Blocking interleukin (IL)4- and IL13-mediated phosphorylation of STAT6 (Tyr641) decreases M2 polarization of macrophages and protects against macrophage-mediated radioresistance of inflammatory breast cancer[J]. Int J Radiat Oncol Biol Phys, 2018, 100(4): 1034-1043.
[24]
Gangadaran P, Gunassekaran GR, Rajendran RL, et al. Interleukin-4 receptor targeting peptide decorated extracellular vesicles as a platform for in vivo drug delivery to thyroid cancer[J]. Biomedicines, 2022, 10(8): 1978.
[25]
Sarangthem V, Yi A, Kim Y, et al. Therapeutic effect of IL-4 receptor-targeting pro-apoptotic peptide (AP1-ELP-KLAK) in glioblastoma tumor model[J]. Int J Nanomedicine, 2021, 16: 5039-5052.
[26]
De Groot AE, Myers KV, Krueger TEG, et al. Targeting interleukin 4 receptor α on tumor-associated macrophages reduces the pro-tumor macrophage phenotype[J]. Neoplasia, 2022, 32: 100830.
[27]
Fieldes M, Bourguignon C, Assou S, et al. Targeted therapy in eosinophilic chronic obstructive pulmonary disease[J]. ERJ Open Res, 2021, 7(2): 00437-2020.
[28]
Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts[J]. N Engl J Med, 2023, 389(3): 205-214.
[29]
Deleuran M, Thaçi D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study[J]. J Am Acad Dermatol, 2020, 82(2): 377-388.
[30]
康诺亚生物医药科技(成都)有限公司. 一种自免疫抑制剂及其应用: 中国, WO2019228405A1[P]. 2019-12-05.
[31]
Zhao Y, Zhang J, Yang B, et al. Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 2b trial[J]. Chin Med J (Engl), 2023, doi: 10.1097/CM9.0000000000002747.
[32]
Zhang Y, Yan B, Shen S, et al. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial[J]. E Clin Med, 2023, 61: 102076.
[33]
Zhang J, Li P, Guo J, et al. CBP-201, a next-generation IL-4Rα antibody, achieved all primary and sec-ondary efficacy endpoints in the treatment of adults with moderate-to-severe atopic dermatitis (AD): a randomized, double-blind, pivotal trial in China (CBP-201-CN002)[C]//Proceedings of the American Academy of Dermatology 2023 Annual Meeting, New Orleans: American Academy of Dermatology, 2023: 17-21.
[34]
Silverberg JI, Strober B, Feinstein B, et al. Efficacy and safety of rademikibart (CBP-201), a next-generation monoclonal antibody targeting IL-4Rα, in adults with moderate-to-severe atopic dermatitis: a phase 2 randomized trial (CBP-201-WW001)[J]. J Allergy Clin Immunol, 2023, doi: 10.1016/j.jaci.2023.11.924.
[35]
Matschiner G, Fitzgerald MF, Moebius U, et al. Elarekibep (PRS-060/AZD1402), a new class of inhaled Anticalin medicine targeting IL-4Ra for type 2 endotype asthma[J]. J Allergy Clin Immunol, 2023, 151(4): 966-975.
[36]
BioSpace. Pieris pharmaceuticals announces successful completion of safety milestone and initiation of efficacy portion of phase 2a trial of PRS-060/AZD1402[EB/OL]. [2023-08-01]. https://www.biospace.com/article/releases/pieris-pharmaceuticals-announces-successful-completion-of-safety-milestone-and-initiation-of-efficacy-portion-of-phase-2a-trial-of-prs-060-azd1402/?keywords=PRS-060%2fAZD1402.
[37]
新药情报库. 重组抗IL-4Rα人源化单克隆抗体(上海三生国健)[EB/OL]. [2023-08-01]. https://synapse.zhihuiya.com/drug/1dc16e5e570d42b7b8d5bfd78969392b.
[38]
洛启生物. 抗IL-4R单域抗体雾化液[J].[EB/OL]. [2023-08-01]. http://www.novamab.com/product/1.html.
[39]
南京融捷康生物科技有限公司. 一种稳定的抗体制剂: 中国, WO2023226617A1[P]. 2023-11-30
[40]
Walsh JT, Hendrix S, Boato F, et al. MHCⅡ-independent CD4+ T cells protect injured CNS neurons via IL-4[J]. J Clin Invest, 2015, 125(2): 699-714.
[41]
Chylikova J, Dvorackova J, Tauber Z, et al. M1/M2 macrophage polarization in human obese adipose tissue[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2018, 162(2): 79-82.
[42]
Karo-Atar D, Bitton A, Benhar I, et al. Therapeutic targeting of the interleukin-4/interleukin-13 signaling pathway: in allergy and beyond[J]. BioDrugs, 2018, 32(3): 201-220.
2024年第45卷第1期
15
2
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2024.01.012
  • 接收时间:2023-05-19
  • 首发时间:2026-11-18
  • 出版时间:2024-01-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2023-05-19
基金
作者信息
    中国医药工业研究总院,上海 201203

通讯作者:

谢丽萍,研究员,研究方向:生物大分子药物研发。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.01.012
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏